378 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Andra AP fonden

Andra AP fonden bought a new stake in shares of Boston Scientific Co. (NYSE:BSX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 378 shares of the medical equipment provider’s stock, valued at approximately $29,000.

A number of other hedge funds also recently modified their holdings of BSX. Sierra Summit Advisors LLC purchased a new stake in Boston Scientific in the 4th quarter worth about $8,038,000. TD Asset Management Inc lifted its position in shares of Boston Scientific by 10.7% in the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after purchasing an additional 155,565 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in Boston Scientific by 225.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after purchasing an additional 73,219 shares in the last quarter. BDF Gestion acquired a new position in Boston Scientific in the 2nd quarter valued at approximately $3,570,000. Finally, Precision Wealth Strategies LLC purchased a new stake in Boston Scientific in the 4th quarter worth approximately $956,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BSX. TD Cowen upped their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Robert W. Baird raised their price target on Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lifted their price target on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, July 25th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Raymond James boosted their target price on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $85.38.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $83.84 on Friday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $83.84. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The company has a market cap of $123.00 billion, a P/E ratio of 70.45, a P/E/G ratio of 2.71 and a beta of 0.79. The business’s 50 day moving average is $77.94 and its two-hundred day moving average is $73.94.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.58 by $0.04. The firm had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 EPS. On average, equities analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the transaction, the executive vice president now owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 20,949 shares of company stock worth $1,627,877. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.